Conflict of interest: nothing to declare.
Article first published online: 9 MAY 2013
Copyright © 2013 Wiley Periodicals, Inc.
Journal of Cellular Biochemistry
Volume 114, Issue 7, pages 1457–1463, July 2013
How to Cite
Fang, C., Zhao, Y. and Guo, B. (2013), MiR-199b-5p targets HER2 in breast cancer cells. J. Cell. Biochem., 114: 1457–1463. doi: 10.1002/jcb.24487
Chen Fang and Yu Zhao contributed equally to this work.
- Issue published online: 9 MAY 2013
- Article first published online: 9 MAY 2013
- Accepted manuscript online: 7 JAN 2013 08:48AM EST
- Manuscript Accepted: 18 DEC 2012
- Manuscript Received: 7 NOV 2012
- National Natural Science Foundation of China. Grant Number: 30572200
- BREAST CANCER
HER2 (ErbB2) has been reported to be overexpressed in 20–30% of breast cancer and confers poor survival because of high proliferation and metastasis rates. MicroRNAs are small noncoding RNAs that are responsible for the post-transcriptional regulation of target genes. We found miR-199b-5p inhibited HER2 expression by direct targeting its 3′-untranslated region (3′UTR) in breast cancer cells. In addition, miR-199b-5p inhibited HER2 downstream signaling by ERK1/2 and AKT pathways in breast cancer cells. Besides, transwell migration, wound healing, and clonogenicity were obviously inhibited by overexpression of miR-199b-5p in HER2-positive breast cancer cells. We also found that miR-199b-5p could enhance the suppression of trastuzumab on cell migration and clonogenicity. These results suggest that miR-199b-5p may have the potential to be a novel important alternative therapeutic target for HER2-positive breast cancer. J. Cell. Biochem. 114: 1457–1463, 2013. © 2013 Wiley Periodicals, Inc.